Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026
Rhea-AI Summary
Carlsmed (Nasdaq: CARL) will report fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will host a conference call and concurrent webcast at 1:30 PM Pacific Time, with a replay archived on the company's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CARL declined 5.78%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $18M from the company's valuation, bringing the market cap to $294M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves with both declines and gains; CARL’s slight -0.08% move does not clearly track a unified sector trend.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Product usage milestone | Positive | -0.1% | First aprevo lumbar bi-lateral posterior fusion procedure at Colorado hospital. |
| Jan 12 | Preliminary revenue update | Positive | +13.8% | Preliminary Q4 and 2025 revenue with strong year-over-year growth and user gains. |
| Jan 06 | Clinical data publication | Positive | +2.9% | Two-year lumbar data showing lower revision rates versus conventional implants. |
| Dec 16 | Conference participation | Neutral | +0.0% | Planned presentation and investor meetings at J.P. Morgan 2026 Healthcare Conference. |
| Dec 03 | Product launch | Positive | +12.4% | U.S. launch of aprevo cervical platform with early clinical experience data. |
Recent news with strong growth, clinical data, and product launches often coincided with positive price reactions, with one divergence on a procedure milestone.
This announcement schedules the formal Q4 and full-year 2025 earnings release, following several growth and product milestones. On Jan 12, 2026, CARL reported strong preliminary 2025 revenue growth with a double‑digit positive price reaction. Earlier, a Jan 6, 2026 clinical data publication and the Dec 3, 2025 U.S. launch of the aprevo cervical platform also drew positive responses. A first bilateral lumbar procedure on Feb 10, 2026 saw a flat reaction, highlighting some variability in how operational milestones are priced.
Market Pulse Summary
The stock moved -5.8% in the session following this news. A negative reaction despite this being mainly an earnings-timing announcement would fit occasional divergence seen around operational updates, such as the flat move after the first bilateral lumbar procedure despite its positive tone. Prior filings highlight expanding credit facilities and ongoing losses alongside strong revenue growth, which may have heightened sensitivity to future guidance or margin commentary that the scheduled earnings call could reveal.
AI-generated analysis. Not financial advice.
CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, February 25, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time.
Conference Call Information
To participate in this event, dial in approximately 5 to 10 minutes before the start of the conference call.
Event Date: Wednesday, February 25, 2026
Time: 1:30 PM Pacific Time
Participant Registration: https://register-conf.media-server.com/register/BIb4506be22c484ba7a7767032cba20986
A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the company's website here.
About Carlsmed
Carlsmed is a medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond.
Investor Relations
IR@Carlsmed.com
Media
LeAnn Burton
Senior Director Brand Marketing
LBurton@Carlsmed.com
FAQ
When will Carlsmed (CARL) release its Q4 and full year 2025 results?
What time is the Carlsmed (CARL) earnings conference call on February 25, 2026?
How can investors join the Carlsmed (CARL) Feb 25, 2026 earnings webcast?
Will Carlsmed (CARL) provide a replay of the February 25, 2026 earnings call?
What topics will Carlsmed (CARL) management likely cover in the February 25, 2026 call?
Is prior registration required to attend Carlsmed's (CARL) Feb 25, 2026 earnings call?
